Single “maximal” dose of Ivermectin (400 mcg/kg of patient body weight) shows some mild benefit in small Spanish double blind, placebo controlled “gold standard” clinical trial of 24 young (age 19 to 44) patients who were 50/50 male/female.
The research team gave one single dose of ivermectin or placebo to 24 patients with confirmed infection and mild symptoms, within the first 72 hours after the first symptoms started. Nasal swabs and blood samples were taken at the moment of enrolment and one, two and/or three weeks after treatment.
Seven days after treatments, no difference was observed in the percentage of PCR-positive patients (100% of patients were positive in both groups). However, the mean viral load in the ivermectin-treated group was lower (around 3x lower at four days and up to 18x lower at seven days post-treatment), although the difference was not statistically significant. Treated patients also showed a reduced duration of certain symptoms (of 50% for loss of smell and taste and of 30% for cough).
All patients developed virus-specific IgG but, again, the mean level of antibodies in the Ivermectin treated group was lower than in the placebo group. "This could be the result of a lower viral load in these patients," explains Chaccour.
The fact that there was no effect on duration of symptoms or markers associated with inflammation suggests that ivermectin may act through mechanisms that do not involve a possible anti-inflammatory effect. The authors believe it could be interfering with viral entry in the cells, as suggested by another study performed in hamsters at the Pasteur Institute.
end quote
Gotta wonder if it would even better if maximal doses were given every day in much older patients?
Last edited by 360view; 01/20/2109:56 AM. Reason: added 400 mcg/kg after reading full paper
